comprehensive -WSS

comprehensive

author：knowledge 2025-10-01 20:15:47 - browse：6

Kidney transplants are the most common organ transplant procedure in the U.S., with 25,000 taking place in 2022. But for patients who receive new kidneys, the transplant is often followed by severe lifelong challenges, many of which are linked to the immunosuppression drug regimen required after surgery to ensure the body does not reject the new organ. These treatments have side effects and toxicities that impact patients’ long-term health, and even survival, leading to a transplant failure rate of 30-50% at the 10-year mark.

Now a new trial sponsored by Medeor Therapeutics, the results of which were presented Thursday at the American Society of Nephrology (ASN) Kidney Week 2023 Annual Meeting, offers hope that stem cell therapy may help patients discontinue their immunosuppressant regime within a year of the transplant.

“The ability to get a transplant without being on lifelong immunosuppression is kind of a dream in transplant, so I can see why this would generate a lot of excitement,” said Sommer Gentry, a professor of surgery at New York University, who was not involved in the study and was not at the actual presentation, but reviewed the trial’s presentation slides.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： Why sickle cell disease is getting the first CRISPR treatment

WSS

Juul documents reveal insider tactics on political lobbying

CMS should re

Here’s what’s in the FDA plan to include pregnant women in clinical trials

STAT Boddities: What happens to the brain when we get scared?

AMAs digital advisors table RPM coding reform proposal, again

Chemotherapy shortages won’t get better under Biden’s latest plan

hotspot

comprehensive

Wikipedia

BioMarin wins approval for gene therapy to treat hemophilia A

Congress considering partial increase for doctor pay in Medicare

ChatGPT in medicine: STAT answers readers' burning questions

What PEPFAR has meant on the ground in Ukraine

Heart attack and stroke risk calculators need revising

Sanofi says it has 12 blockbusters on the way. Will investors believe it?

Tori Bowie and the unacceptable rates of Black maternal death

Websites selling Wegovy, Zepbound ingredients targeted by FDA

Jerome Adams on the need for new antivirals for Covid

Sanofi says it has 12 blockbusters on the way. Will investors believe it?

leisure time

What causes an itch? Researchers may have solved the mystery

Pharma patents targeted by Biden in move to slash drug prices

Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

Radiology is caught between AI's potential and concern for patients

Amylyx and the next ALS drug test, plus a chat with CRISPR's CEO

FDA needs staff influx to meet gene therapy needs, Marks says

leisure time

hotspot

focus

explore